Target Protein: CEBP-alpha
Specificity: Due to the similarity in amino acid composition of this protein and the closely related CEBP-beta, this antibody may be cross-react with this protein due to a 77% non-sequential sequence similarity.
Immunogen Range: 251-358/358
Entrez Gene: 1050
Swiss Prot: P49715
Source: KLH conjugated synthetic peptide derived from human CEBP-alpha
Purification: Purified by Protein A.
Storage Buffer: Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide.
Storage Condition: Store at -20°C for 12 months..
Background: Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes (PubMed:11242107). During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung (By similarity). Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage (By similarity). To regulate these different processes at the proper moment and tissue, interplays with other transcription factors and modulators. Downregulates the expression of genes that maintain cells in an undifferentiated and proliferative state through E2F1 repression, which is critical for its ability to induce adipocyte and granulocyte terminal differentiation. Reciprocally E2F1 blocks adipocyte differentiation by binding to specific promoters and repressing CEBPA binding to its target gene promoters. Proliferation arrest also depends on a functional binding to SWI/SNF complex (PubMed:14660596). In liver, regulates gluconeogenesis and lipogenesis through different mechanisms. To regulate gluconeogenesis, functionally cooperates with FOXO1 binding to IRE-controlled promoters and regulating the expression of target genes such as PCK1 or G6PC. To modulate lipogenesis, interacts and transcriptionally synergizes with SREBF1 in promoter activation of specific lipogenic target genes such as ACAS2. In adipose tissue, seems to act as FOXO1 coactivator accessing to ADIPOQ promoter through FOXO1 binding sites (By similarity).
Cross Reactive Species:
Predicted Cross Reactive Species:
For research use only. Not intended for diagnostic or therapeutic use.